Company / Accounts Receivable
Sunshine Biopharma Inc. Accounts Receivable History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$3.5M
FY2025
5-year range
$7.8K / $3.9M
FY2021-FY2025
Trend
-10.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $3M to $3M over the past 2 years.
Based on SEC 10-K filings.
$3M in FY2025 with a 5-year CAGR of +348.1%.
Improved from $3M to $3M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +21.9%
- 5-Year CAGR
- +348.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +348.1%, indicating consistent growth.
- In FY2025, accounts receivable decreased 10.6% year-over-year.
- Peak accounts receivable was recorded in FY2024.
- Lowest accounts receivable in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.5M | -10.6% |
| FY2024 | $3.9M | +51.6% |
| FY2023 | $2.6M | +33.5% |
| FY2022 | $1.9M | +24421.1% |
| FY2021 | $7.8K | +307.0% |
| FY2020 | $1.9K | +345.6% |
| FY2019 | $430 | -99.5% |
| FY2018 | $95.0K | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026